Cargando…
Serum-Derived Bovine Immunoglobulin Stimulates SCFA Production by Specific Microbes in the Ex Vivo SIFR(®) Technology
Serum-derived bovine immunoglobulins (SBI) exert health benefits mediated by their ability to bind microbial components, thereby preventing translocation and subsequent inflammation. While in vivo studies have shown that a fraction of SBI also reaches the colon, little is known about the impact of S...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053870/ https://www.ncbi.nlm.nih.gov/pubmed/36985232 http://dx.doi.org/10.3390/microorganisms11030659 |
_version_ | 1785015515886911488 |
---|---|
author | Van den Abbeele, Pieter Detzel, Christopher Rose, Alexis Deyaert, Stef Baudot, Aurélien Warner, Christopher |
author_facet | Van den Abbeele, Pieter Detzel, Christopher Rose, Alexis Deyaert, Stef Baudot, Aurélien Warner, Christopher |
author_sort | Van den Abbeele, Pieter |
collection | PubMed |
description | Serum-derived bovine immunoglobulins (SBI) exert health benefits mediated by their ability to bind microbial components, thereby preventing translocation and subsequent inflammation. While in vivo studies have shown that a fraction of SBI also reaches the colon, little is known about the impact of SBI on the dense colonic microbiota that has great potential to impact human health. This study, therefore, investigated the impact of three bovine plasma protein fractions (SBI, bovine plasma (BP) and albumin-enriched bovine plasma (ABP)) on the gut microbiota of six human adults using the novel ex vivo SIFR(®) technology, recently demonstrated to generate predictive findings for clinical studies. When dosed at an equivalent of 5 g/day, all protein fractions significantly increased health-related metabolites—acetate, propionate, and butyrate. Upon simulating small intestinal absorption, SBI still markedly increased acetate and propionate, demonstrating that SBI is more resistant to small intestinal digestion and absorption compared to the other protein sources. Despite noticeable interindividual differences in microbiota composition among human adults, SBI consistently stimulated a narrow spectrum of gut microbes, which largely differed from the ones that are typically involved in carbohydrate fermentation. The SBI-fermenting consortium included B. vulgatus and L. edouardi (correlating with acetate and propionate) along with Dorea longicatena, Coprococcus comes and the butyrate-producing bacterium SS3/4 (correlating with butyrate). Overall, this study revealed that protein bovine fractions can contribute to health benefits by specifically modulating the human gut microbiota. While health benefits could follow from the production of SCFA, a broader range of protein-derived metabolites could also be produced. This study also confirms that the concept of prebiotics (substrates selectively utilized by host microorganisms conferring a health benefit) could go beyond the use of ingestible carbohydrates and extend to partially indigestible proteins. |
format | Online Article Text |
id | pubmed-10053870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100538702023-03-30 Serum-Derived Bovine Immunoglobulin Stimulates SCFA Production by Specific Microbes in the Ex Vivo SIFR(®) Technology Van den Abbeele, Pieter Detzel, Christopher Rose, Alexis Deyaert, Stef Baudot, Aurélien Warner, Christopher Microorganisms Article Serum-derived bovine immunoglobulins (SBI) exert health benefits mediated by their ability to bind microbial components, thereby preventing translocation and subsequent inflammation. While in vivo studies have shown that a fraction of SBI also reaches the colon, little is known about the impact of SBI on the dense colonic microbiota that has great potential to impact human health. This study, therefore, investigated the impact of three bovine plasma protein fractions (SBI, bovine plasma (BP) and albumin-enriched bovine plasma (ABP)) on the gut microbiota of six human adults using the novel ex vivo SIFR(®) technology, recently demonstrated to generate predictive findings for clinical studies. When dosed at an equivalent of 5 g/day, all protein fractions significantly increased health-related metabolites—acetate, propionate, and butyrate. Upon simulating small intestinal absorption, SBI still markedly increased acetate and propionate, demonstrating that SBI is more resistant to small intestinal digestion and absorption compared to the other protein sources. Despite noticeable interindividual differences in microbiota composition among human adults, SBI consistently stimulated a narrow spectrum of gut microbes, which largely differed from the ones that are typically involved in carbohydrate fermentation. The SBI-fermenting consortium included B. vulgatus and L. edouardi (correlating with acetate and propionate) along with Dorea longicatena, Coprococcus comes and the butyrate-producing bacterium SS3/4 (correlating with butyrate). Overall, this study revealed that protein bovine fractions can contribute to health benefits by specifically modulating the human gut microbiota. While health benefits could follow from the production of SCFA, a broader range of protein-derived metabolites could also be produced. This study also confirms that the concept of prebiotics (substrates selectively utilized by host microorganisms conferring a health benefit) could go beyond the use of ingestible carbohydrates and extend to partially indigestible proteins. MDPI 2023-03-04 /pmc/articles/PMC10053870/ /pubmed/36985232 http://dx.doi.org/10.3390/microorganisms11030659 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Van den Abbeele, Pieter Detzel, Christopher Rose, Alexis Deyaert, Stef Baudot, Aurélien Warner, Christopher Serum-Derived Bovine Immunoglobulin Stimulates SCFA Production by Specific Microbes in the Ex Vivo SIFR(®) Technology |
title | Serum-Derived Bovine Immunoglobulin Stimulates SCFA Production by Specific Microbes in the Ex Vivo SIFR(®) Technology |
title_full | Serum-Derived Bovine Immunoglobulin Stimulates SCFA Production by Specific Microbes in the Ex Vivo SIFR(®) Technology |
title_fullStr | Serum-Derived Bovine Immunoglobulin Stimulates SCFA Production by Specific Microbes in the Ex Vivo SIFR(®) Technology |
title_full_unstemmed | Serum-Derived Bovine Immunoglobulin Stimulates SCFA Production by Specific Microbes in the Ex Vivo SIFR(®) Technology |
title_short | Serum-Derived Bovine Immunoglobulin Stimulates SCFA Production by Specific Microbes in the Ex Vivo SIFR(®) Technology |
title_sort | serum-derived bovine immunoglobulin stimulates scfa production by specific microbes in the ex vivo sifr(®) technology |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053870/ https://www.ncbi.nlm.nih.gov/pubmed/36985232 http://dx.doi.org/10.3390/microorganisms11030659 |
work_keys_str_mv | AT vandenabbeelepieter serumderivedbovineimmunoglobulinstimulatesscfaproductionbyspecificmicrobesintheexvivosifrtechnology AT detzelchristopher serumderivedbovineimmunoglobulinstimulatesscfaproductionbyspecificmicrobesintheexvivosifrtechnology AT rosealexis serumderivedbovineimmunoglobulinstimulatesscfaproductionbyspecificmicrobesintheexvivosifrtechnology AT deyaertstef serumderivedbovineimmunoglobulinstimulatesscfaproductionbyspecificmicrobesintheexvivosifrtechnology AT baudotaurelien serumderivedbovineimmunoglobulinstimulatesscfaproductionbyspecificmicrobesintheexvivosifrtechnology AT warnerchristopher serumderivedbovineimmunoglobulinstimulatesscfaproductionbyspecificmicrobesintheexvivosifrtechnology |